The Pentagon’s after a faster, more reliable way to fight pandemics and viral terror threats by mass producing vaccines. So far, plant-based approaches seem to be their top pick to replace old-school methods. Now, in a bid to hasten the development of vaccines that are ready for human use before the next H1N1 emerges, the military’s looking for a little help from our northern neighbors.
Darpa, the Pentagon’s blue-sky research arm, handed out $21 million to Canadian biotech firm Medicago Inc. The company, based in Quebec City, will use the money to build a 90,000-square-foot facility that’ll use tobacco plants to produce 10 million monthly doses of influenza vaccine.
The funding is a smaller part of Darpa’s burgeoning Accelerated Manufacture of Pharmaceuticals (AMP) program, which aims to revolutionize current, egg-based vaccine production models, and yield vaccines within three months of “emerging and novel biological threats.” In February, the agency gave $21 million to Texas A&M for the construction of a 145,000 square-foot “biotherapeutic production facility” that uses mobile “pods” to grow vaccine-infused tobacco plants.
Continue Reading “Darpa Turns to Canadian Tobacco to Fight Viral Terror” »